🔗 Share this article

Former Prime Minister Rishi Sunak has strengthened his call for a targeted screening programme for prostate gland cancer.

In a recent discussion, he declared being "convinced of the immediate need" of implementing such a initiative that would be cost-effective, feasible and "protect innumerable lives".

These statements come as the National Screening Advisory Body reviews its decision from half a decade past not to recommend routine screening.

Media reports propose the committee may continue with its current stance.

Olympic Champion Adds Support to Campaign

Olympic cycling champion Sir Chris Hoy, who has advanced prostate gland cancer, supports middle-aged males to be screened.

He suggests reducing the eligibility age for obtaining a prostate-specific antigen laboratory test.

Presently, it is not routinely offered to healthy individuals who are under 50.

The prostate-specific antigen screening is controversial however. Levels can elevate for reasons apart from cancer, such as bacterial issues, resulting in incorrect results.

Critics contend this can lead to unwarranted procedures and adverse effects.

Targeted Testing Proposal

The suggested screening programme would concentrate on men aged 45–69 with a family history of prostate gland cancer and black men, who encounter increased susceptibility.

This population includes around over a million individuals in the United Kingdom.

Organization calculations suggest the programme would cost £25m annually - or about eighteen pounds per patient - akin to intestinal and breast examination.

The projection includes 20% of eligible men would be contacted each year, with a 72% participation level.

Medical testing (imaging and biopsies) would need to expand by almost a quarter, with only a moderate growth in healthcare personnel, as per the study.

Medical Professionals Response

Various healthcare professionals are sceptical about the value of examination.

They argue there is still a risk that individuals will be treated for the cancer when it is not absolutely required and will then have to experience side effects such as incontinence and impotence.

One respected urological specialist stated that "The problem is we can often find conditions that may not require to be treated and we risk inflicting harm...and my worry at the moment is that harm to benefit ratio isn't quite right."

Individual Experiences

Patient voices are also shaping the conversation.

A particular example concerns a 66-year-old who, after requesting a PSA test, was detected with the disease at the age of 59 and was told it had spread to his hip region.

He has since undergone chemotherapy, radiotherapy and hormone treatment but remains incurable.

The man advocates testing for those who are potentially vulnerable.

"This is crucial to me because of my boys – they are 38 and 40 – I want them tested as soon as possible. If I had been tested at 50 I am certain I would not be in the position I am currently," he stated.

Future Steps

The National Screening Committee will have to evaluate the data and perspectives.

While the new report says the ramifications for personnel and availability of a testing initiative would be feasible, opposing voices have contended that it would take imaging resources away from patients being treated for alternative medical problems.

The continuing discussion underscores the complex balance between timely diagnosis and likely excessive intervention in prostate cancer care.